Efficient Brain Delivery of Neuroprotective Antibodies

About the Research Project
Program
Award Type
Standard
Award Amount
$200,000
Active Dates
July 01, 2022 - December 30, 2024
Grant ID
A2022050S
Co-Principal Investigator(s)
Colin Greineder, PhD, University of Michigan
Henry Paulson, MD, PhD, University of Michigan
Geoffrey Murphy, PhD, University of Michigan
Goals
We seek to test a novel approach for delivering antibodies across the blood-brain barrier and stimulating neuroprotective signaling in the brain in a safe and effective manner.
Summary
First, we will evaluate the time-dependent concentrations of our neuroprotective antibody in the brains of mice to optimize intravenous dosing. Next, we will evaluate the levels of neuroprotective receptor activation as a function of time to further optimize dosing to maintain receptor activation over therapeutically relevant timescales. Finally, we will evaluate off-target impacts of receptor activation outside the brain to identify the maximum tolerated doses.
Unique and Innovative
The most innovative aspect of our proposal is the development of a bispecific antibody that efficiently penetrates the blood-brain barrier and induces neuroprotective signaling. Our approach targets an understudied transport pathway into the brain, which leads to extended brain retention and enhanced neuroprotective receptor activation.
Foreseeable Benefits
We expect our research will improve the delivery of diverse therapeutic antibodies to the brain, which is broadly important for treating disorders ranging from neurodegenerative diseases (Alzheimer’s, Parkinson’s and dementias) to brain cancer, stroke and mental disorders. We also expect this research will critically evaluate the potential for safely activating neuroprotective receptors in the brain without inducing off-target toxicity.
Related Grants
Alzheimer's Disease Research
The Astrocyte Cell Surface Proteome in Alzheimer’s Disease
Active Dates
July 01, 2025 - June 30, 2027

Principal Investigator
Omar Peña-Ramos, PhD
Current Organization
Baylor College of Medicine
Alzheimer's Disease Research
Unraveling the Triggers to Myelin Damage in Alzheimer’s Disease
Active Dates
July 01, 2025 - June 30, 2028

Principal Investigator
Katerina Akassoglou, PhD
Current Organization
Gladstone Institutes
Alzheimer's Disease Research
The Role of DYRK1A in Altered Microglia Biology in a Cellular Model of Alzheimer’s Disease in Down Syndrome
Active Dates
January 01, 2025 - December 31, 2027

Principal Investigator
Frances Wiseman, PhD
Current Organization
University College London (UK)